Why the study?
The study aimed to evaluate the association between the remnant cholesterol-inflammation index, which reflects metabolic and inflammatory risks, and the risk of MACE in patients with angina undergoing PCI.
Does a higher baseline remnant cholesterol-inflammation index (RCII) increase the risk of major adverse cardiovascular events (MACE) in patients with angina undergoing PCI?
Does a higher baseline remnant cholesterol-inflammation index (RCII) increase the risk of major adverse cardiovascular events (MACE) in patients with angina undergoing PCI?
Answers are grounded in this paper and cite their sources.
Baseline RCII is significantly and non-linearly associated with an increased risk of MACE in patients with angina undergoing PCI, suggesting its potential as a prognostic biomarker.
Background The remnant cholesterol-inflammation index (RCII), which combines remnant cholesterol (RC) and high-sensitivity C-reactive protein (hs-CRP), reflects both metabolic and inflammatory risks. This study aims to evaluate the association between RCII and the risk of major adverse cardiovascular events (MACE) in patients with angina undergoing percutaneous coronary intervention (PCI). Methods The association between baseline RCII and MACE risk was evaluated using multivariable Cox regression, restricted cubic spline (RCS) analysis, and time-dependent receiver operating characteristic (ROC) curves. Results A total of 2,171 angina patients undergoing PCI were included (mean age 65.32 ± 6.85 years, 61.4% male), with a median follow-up of 36 months, during which 363 MACE events (16.7%) occurred. In the fully adjusted Cox model, each standard deviation increase in RCII was associated with a 5% higher MACE risk (HR = 1.05, 95%CI: 1.04–1.07); compared with the lowest tertile, the HRs for T2 and T3 were 2.87 (95%CI: 2.03–4.04) and 4.42 (95%CI: 3.09–6.32). Subgroup analysis revealed that RCII was significantly associated with MACE risk across different age groups (<65 years and ≥65 years), sex, smoking status, and the presence of coronary artery disease (CAD) history, diabetes, and hypertension, with no significant interactions observed between subgroups. RCS analysis revealed a non-linear positive association ( P for non-linearity < 0.001). Time-dependent ROC analysis showed moderate discriminatory ability, with AUCs of 0.786 (12 months), 0.769 (18 months), 0.741 (24 months), and 0.739 (30 months). Conclusion Baseline RCII may be a potential clinical biomarker for assessing the risk of new-onset MACE in patients with angina undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: